Dr. Michael Lockshin graduated from Harvard College and Harvard Medical School; he did his residencies at Second (Cornell) Medical Service at Bellevue Hospital and Memorial-Sloan Kettering Hospital, and his rheumatology fellowship at Columbia-Presbyterian Hospital. A member of the faculty of Weill Cornell Medical College and a staff rheumatologist at Hospital for Special Surgery and New York Hospital from the 1970s to 1989, he became Extramural Director, then Acting Director of the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases in 1989.
He returned to Hospital for Special Surgery in April of 1997, and is now the director of the Barbara Volcker Center for Women and Rheumatic Disease at Hospital for Special Surgery and professor of medicine and obstetrics-gynecology at Weill Cornell Medical College. He is the author of nearly 300 research papers, book chapters, and books, most on the topic of lupus, pregnancy, antiphospholipid syndrome, and sex differences in disease. From 2005-2010 he was Editor-in-Chief of Arthritis & Rheumatism, rheumatology's premier journal.
His latest book, co-authored with his patient, Alida Brill, and entitled Dancing at the River's Edge: A Patient and her Doctor Negotiate Life with Chronic Illness, is a memoir about their shared experience in treating her autoimmune disease.
Attending Physician, Hospital for Special Surgery
Professor of Medicine and OB-GYN, Weill Cornell Medical College
Director, Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery
Co-Director, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery
Gender and rheumatic disease
Pregnancy and rheumatic disease
Antiphospholipid antibody syndrome
Neurological systemic lupus erythematosus (SLE)
Various national offices, national and international visiting professorships
Institute of Medicine Committee
"Best Doctors in New York," New York Magazine, 2010
One of the goals of Hospital for Special Surgery (HSS) is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.
As part of the disclosure process, this website lists physician collaborations with outside companies if payments were received during the prior year, or if the HSS physician currently receives payment. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.
As of February 27, 2014, Dr. Lockshin reported no financial interest relationships with healthcare industry.
By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, HSS’ Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.
MD, Harvard Medical School, Cambridge, Massachusetts, 1963
Second (Cornell) Medical Service, New York
Bellevue Hospital, New York
Memorial Sloan-Kettering Hospital, New York
Columbia-Presbyterian Medical Center, New York
Internal Medicine, 1969
Chairman, Rheumatology Subspecialty Board, 1983-86
For more publications, please see the PubMed listing.
Dr. Michael Lockshin has a long-term interest in clinical aspects of systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), and pregnancy in rheumatic disease patients. He is Director of the HSS unit participating in the multi-site Lupus Clinical Trials Consortium. With Dr. Melanie Harrison, and funded by the Mary Kirkland Center for Lupus Research and the National Institutes of Health, he is investigating prevalence, mechanisms, and potential treatments for cognitive dysfunction in SLE and APS. With Dr. Doruk Erkan, he participates in the Antiphospholipid Syndrome Registry (APSCORE), funded by NIH, and in a number of specific projects reflecting relative risks, outcomes, and treatments of APS. With Dr. Jane Salmon, he contributes patients to and participates in planning for an NIH-funded study of mechanisms of pregnancy loss in APS and SLE (PROMISSE), as well as in a now-completed study on atherosclerosis in SLE and rheumatoid arthritis. Dr. Lockshin also has a long-standing interest in sex differences in disease incidence; he convened a conference on this topic in 1999 and participated in an Institute of Medicine review of this topic.